# Signals Article on Putative Target P21980 for Celiac Disease
Background
The protein encoded by the putative target P21980 has emerged as a candidate of interest in the study of celiac disease, an autoimmune disorder triggered by the ingestion of gluten in genetically predisposed individuals. Preliminary findings suggest that P21980 may play a role in the immune response and intestinal barrier function, indicating its potential as a therapeutic target. Given the multifactorial nature of celiac disease, further investigation into the molecular mechanisms involving this protein is essential for developing effective treatment strategies.Data-mining rationale
Our analysis utilized the GeoMicroarrayReanalysis approach, cross-referencing reviewed human entries in the UniProt database for "celiac disease" against 29 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). The candidate UniProt:P21980 was identified as being present in several expression-profiling studies, yet it notably lacks any registered Phase 1 or higher clinical programs. This observation raises questions about its potential role in celiac disease and underscores the need for further exploration.Why prior analyses may have missed this
Many of the GEO datasets analyzed predate the implementation of modern empirical-Bayes statistical methods, such as the limma package, which provides robust multiple-testing correction. Consequently, previous analyses may not have accurately captured the expression dynamics of P21980 in the context of celiac disease. The absence of rigorous statistical validation could explain why this candidate has not been prioritized in the search for therapeutic targets in celiac disease.Reasoning for further validation
To substantiate the potential role of P21980 in celiac disease, several experimental approaches are warranted: 1. Re-analyze the matched GEO datasets using the limma package with a Benjamini-Hochberg false discovery rate (FDR) threshold of < 0.05 to identify differentially expressed genes with greater confidence. 2. Validate the top differentially expressed genes, including P21980, by quantitative PCR (qPCR) in an independent cohort of celiac disease patients to confirm expression patterns. 3. Investigate the tissue specificity of P21980 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to determine its relevance in intestinal tissues. 4. Utilize pathway analysis tools like STRING and OmniPath to contextualize P21980 within known biological pathways related to inflammation and celiac disease. 5. If validation is achieved, assess the druggability of P21980 through databases such as DGIdb and ChEMBL to explore potential therapeutic interventions.References
- [UniProt: P21980](https://www.uniprot.org/uniprot/P21980)
- [UniProt: Q2LD37](https://www.uniprot.org/uniprot/Q2LD37)
- [UniProt: P16410](https://www.uniprot.org/uniprot/P16410)
- [UniProt: Q9UQQ2](https://www.uniprot.org/uniprot/Q9UQQ2)
- [UniProt: P51692](https://www.uniprot.org/uniprot/P51692)
- [NCBI GEO Accession GDS:200164883](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200164883)
- [NCBI GEO Accession GDS:200168439](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200168439)
- [NCBI GEO Accession GDS:200138297](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200138297)
- [NCBI GEO Accession GDS:200112102](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200112102)
- [NCBI GEO Accession GDS:200113469](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200113469)